Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

Sofosbuvir + Ribavirin To Be Studied in Children and Adolescents with Hepatitis C

A Phase 2 clinical trial is now underway to evaluate sofosbuvir (Sovaldi) plus ribavirin for children and adolescents, ages 3-17 years, with hepatitis C virus genotypes 2 or 3. Another study will follow to test the forthcoming sofosbuvir/ledipasir coformulation in pediatric patients.

alt

Read more:

ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. While most patients experienced some adverse events, serious side effects were rare and few people discontinued treatment early for this reason.

alt

Read more:

ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients

AbbVie's interferon-free 3D regimen containing ABT-450, ombitasvir, and dasabuvir led to sustained virological response in nearly 100% of people with genotype 1b chronic hepatitis C regardless of unfavorable patient or viral characteristics, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more:

Coverage of the Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.

Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.

Full listing of coverage by topic

ICAAC 2014 website

9/8/14

alt

ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Read more: